Forecasted COVID-19 vaccine revenue share globally by technology 2026

Published by
Matej Mikulic,
Nov 5, 2021
In 2026, around 85 percent of all forecasted revenue generated by COVID-19 vaccines is expected to be generated by mRNA vaccines. This statistic illustrates the forecasted share of COVID-19 vaccine revenues by technology.

Forecasted share of COVID-19 vaccine revenue worldwide in 2021 and 2026, by technology

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

July 2021

Region

Worldwide

Survey time period

as of July 2021

Supplementary notes

Percentage points missing/exceeding 100 percent are probably due to rounding.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " mRNA technology "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you mRNA technology

Overview

5

Research and development

5

COVID-19

6

Leading companies

4

Focus: Moderna

5

Focus: BioNTech

4

Further Content: You might find this interesting as well

Topics

Global pharmaceutical industryPfizerBioNTechVaccinations in the U.S.Coronavirus disease (COVID-19) pandemic
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.